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Background. Mortality from cryptoccocal meningitis remains high. The ACTA trial demonstrated that, compared with 2 weeks 
of amphotericin B (AmB) plus flucystosine (5FC), 1 week of AmB and 5FC was associated with lower mortality and 2 weeks of oral 
flucanozole (FLU) plus 5FC was non-inferior. Here, we assess the cost-effectiveness of these different treatment courses.
Methods. Participants were randomized in a ratio of 2:1:1:1:1 to 2 weeks of oral 5FC and FLU, 1 week of AmB and FLU, 1 week 
of AmB and 5FC, 2 weeks of AmB and FLU, or 2 weeks of AmB and 5FC in Malawi, Zambia, Cameroon, and Tanzania. Data on indi-
vidual resource use and health outcomes were collected. Cost-effectiveness was measured as incremental costs per life-year saved, 
and non-parametric bootstrapping was done.
Results. Total costs per patient were US $1442 for 2 weeks of oral FLU and 5FC, $1763 for 1 week of AmB and FLU, $1861 for 1 
week of AmB and 5FC, $2125 for 2 weeks of AmB and FLU, and $2285 for 2 weeks of AmB and 5FC. Compared to 2 weeks of AmB 
and 5FC, 1 week of AmB and 5FC was less costly and more effective and 2 weeks of oral FLU and 5FC was less costly and as effective. 
The incremental cost-effectiveness ratio for 1 week of AmB and 5FC versus oral FLU and 5FC was US $208 (95% confidence interval 
$91–1210) per life-year saved.
Conclusions. Both 1 week of AmB and 5FC and 2 weeks of Oral FLU and 5FC are cost-effective treatments.
Keywords. cryptococcal meningitis; antifungal induction treatments; cost-effectiveness; flucytosine; sub-Saharan Africa.
Mortality from cryptoccocal meningitis (CM) remains high 
in resource-limited settings [1]. The international standard 
induction treatment of 2 weeks of amphotericin B deoxycho-
late (AmB) plus flucytosine (5FC) [2] is not available, while 
the alternative of fluconazole (FLU) monotherapy is associated 
with mortality of 50–60% at 10 weeks and >70% at 1 year [3–5].
The ACTA trial [6] tested new induction strategies, based on 
promising phase 2 data. Both 2 weeks of oral combination ther-
apy with FLU plus flucytosine and 1 week of AmB with either 
FLU or 5FC were compared against the internationally-recom-
mended 2 weeks of AmB with either FLU or 5FC, in a 2:1:1:1:1 
ratio. The aim was to improve upon the efficacy of FLU mono-
therapy with regimens that, unlike 2 weeks of AmB, could be 
more readily sustained in resource-limited settings. The trial 
showed that 1 week of AmB and 5FC was associated with lower 
mortality and the oral combination was non-inferior compared 
with the recommended 2 weeks of AmB and 5FC.
Given the scarcity of resources, detailed evidence on the 
health-care costs of treatment and on the associated health 
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impacts are essential to inform policy decisions. AmB is intra-
venous and requires hospitalization and stringent laboratory 
monitoring, while FLU is oral and available through donation 
programs or as low-cost, generic options. The current availabil-
ity of 5FC is very limited.
To date, there are very few detailed studies of the costs of 
alternative CM treatments. Therefore, within the ACTA trial, 
we conducted a comparative cost-effectiveness study of the 5 
regimens tested, in order to support and guide policy decisions.
METHODS
The ACTA trial [6] was an open-label, phase 3, randomized, 
non-inferiority, multi-center trial that enrolled patients with 
human immunodeficiency virus (HIV)-associated CM from 
9 African centers in 4 countries (Malawi, Zambia, Tanzania, 
and Cameroon) between January 2013 and November 2016. 
Participants were first randomized to 1 of 3 strategies: an oral 
combination regimen, 1 week of AmB, or the standard 2 weeks of 
AmB. Those in the AmB arms were further randomized to 5FC 
or FLU, in a 1:1 ratio, as the partner drug treatment. This resulted 
in 5 arms, with a ratio of 2:1:1:1:1: (1) 2 weeks of oral 5FC and 
FLU; (2) 1 week of AmB and FLU; (3) 1 week of AmB and 5FC; 
(4) 2 weeks of AmB and FLU; and (5) 2 weeks of AmB and 5FC.
A full economic costing and cost-effectiveness analysis of the 
CM treatments was done, using the consolidated health economic 
evaluation reporting standards appraisal guidelines [7], from the 
health-care perspective. Resource use data were collected using an 
ingredients-based approach [8, 9]. The data on individual resource 
use and health outcomes, including trial-related complications 
and treatment of complications, were collected from all partici-
pants onto case-report forms. A detailed costing study was done 
in the Zambian hospital (Table 1 and Supplementary Material). 
CM-specific and overhead costs, including costs of admissions 
and laboratory tests, were collated from the hospital’s financial 
and utilization documents. The treatment-related utilization data 
were collated from the case-report forms. Data were collected on 
lengths of stays in hospitals, types of diagnostic tests, and the med-
ical supplies and drugs used. Discussions were held with relevant 
hospital staff for data triangulation. The ACTA study team were 
consulted on the trial-related expenditure and resource-utilization 
data, in relation to complications. Where unit costs were not avail-
able in the expenditure records, local market prices were used.
A time-and-motion study was conducted to inform the mon-
etary valuation for care provided by health staff at the bedside. 
It collected information on the types and intensities of care 
received by a purposive sample of 59 trial participants. Each 
participant was observed for 2 consecutive days. Findings on 
the time spent on patient care were combined with salaries 
(including all financial benefits) to estimate the total staff costs 
spent on caring for CM patients (Table 1). We collected data on 
health-care resource and unit prices, adjusted them to the 2015 
US$ price level, and included the effects of bulk purchasing and 
delivery/shipping charges. An average annual exchange rate for 
the trial baseline year and subsequent inflation corrections were 
used in the currency conversion and inflation correction.
Aggregated hospital expenditures were allocated proportion-
ally to relevant institutional units and departments. This was 
complemented with observations to establish cost-allocation fac-
tors (eg, floor surface, number of beds, number of medical staff), 
in particular in the allocation of overhead costs. These additional 
costs were disaggregated and summarized in costs per bed-day; 
CM treatment–specific costs and laboratory test costs, according 
to recurrent and capital costs; and non-specific costs of addi-
tional use of antibiotics in relation to complications. Recurrent 
cost items were considered to be goods/services with a life span 
of less than 1  year, whereas capital costs were defined as costs 
which were incurred to purchase good/services that last for more 
than 1 year. Capital costs were few, were limited to those items 
related to diagnostics, and were annualized over their economic 
life (informed by the Zambian hospital’s accounting documents), 
using a discount rate of 3% [9, 10]. The analysis included institu-
tional and department overheads, including for hospital admin-
istration, drugs, and other supply chain management. A detailed 
listing is given in Table 1, while a more detailed description of 
the cost component is presented in the Supplementary Material.
The health outcome included in the cost-effectiveness anal-
ysis is life-year saved, based on the ages of the patients saved 
from dying. Here, we multiplied the additional deaths pre-
vented with the observed, CD4-specific, weighted life expectan-
cies [11]. The average life expectancy of the additional survivors 
was estimated conservatively at 18 years [11]. We did not make 
a long-term quality-of-life adjustment, as the mortality reduc-
tion was substantial and was defined as the main outcome of 
the trial. Quality-of-life outcomes after CM meningitis in these 
patient groups are lacking. We used a differential discount rate 
for health-care costs (3% per international standard) and life-
years gained (0%, as given in the literature) [12, 13].
Statistical Analysis
Total cost—that is, observed use of resources, multiplied 
by a specific unit price, and increased for specific overhead 
costs—was adjusted using a Kaplan–Meier average estimator 
to account for censoring from death or loss to follow-up [14]. 
Individual patient costs were calculated and non-parametric 
bootstrapping was used to draw a stable sample (defined as the 
percentage change in standard deviation between 2 subsequent 
samples [15]) from patient records by treatment arm to allow 
for the skewed distribution of costs and the correlation between 
costs and effectiveness [16].
The 95% confidence intervals for the total cost per patient and the 
probability of death were calculated using the bias-corrected percen-
tile acceleration method [15]. The 5 ACTA treatments were ranked 
by their increasing costs, and we ruled out strategies that were less 
effective and more costly than the comparator (less economically 
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attractive or dominated in economic terms) and strategies that were 
less effective and had a higher incremental cost-effectiveness ratio 
(extended dominance). Of the remaining strategies, incremental 
cost-effectiveness ratios were calculated for each strategy, relative to 
the standard treatment and the next best alternative.
Costs per life-year saved were estimated by dividing mean 
incremental costs by mean number of life-years saved. Cost-
effectiveness planes and an acceptability curve were used to 
show the uncertainties around incremental cost-effectiveness 
ratios. A series of (1-way) sensitivity analyses were done, vary-
ing 1 parameter at a time to address uncertainty in the data 
inputs (including, especially, the observed uncertainty range 
around patient-level resource use shown in Table  2 and the 
uncertainties in the observed mortality rate and observed range 
of life expectancy: 12.8 to 40.81) [17] to compute the uncer-
tainties in incremental cost-effectiveness ratios [18]. Here, the 
parameters in the standard treatment arm were kept constant. 
The effects of the top-ranking individual parameters are pre-
sented by a tornado sensitivity graph.
Ethics
The trial protocol and data collection were approved by the 
London School of Hygiene and Tropical Medicine Research 
Ethics Committee and by the national ethics and regulatory 
bodies in each country. Written informed consent was obtained 
from all participants or, in the case of those with altered mental 
Table 1. Unit Prices (US$ in 2015) by Resource Item and Source of Unit Price
Resource Item Supplies Staff Capital Total Source
Costs per bed-day 9.45 37.06 1.14 47.64 Costing study
Lumber puncture, per time 0.94 7.49 1.14 9.57 Costing study
Biochemistry, per test
 Total bilirubin 1.9 2.63 0.27 4.8 Costing study
 C-reactive protein 5.77 2.63 0.27 8.67 Costing study
 Alanine transaminase 4.04 2.63 0.27 6.94 Costing study
 Magnesium 2.05 2.63 0.27 4.95 Costing study
 Urea 1.94 2.63 0.27 4.84 Costing study
 Creatinine 1.83 2.63 0.27 4.73 Costing study
 Proteinuria 1.96 2.63 0.27 4.86 Costing study
Microbiology, per test
 Urine culture: negative 1.5 5.92 0.43 7.84 Costing study
 Urine culture: positive 2.08 8.65 0.43 11.16 Costing study
 Blood culture: negative 1.03 6.17 0.55 7.74 Costing study
 Blood culture: positive 3.39 9.79 0.55 13.73 Costing study
 Sputum culture: negative 2.13 4.4 0.45 6.98 Costing study
 Sputum culture: positive 4.04 8.02 0.45 12.5 Costing study
 CSF: negative 9.06 13.15 0.46 22.66 Costing study
 CSF: positive 9.98 15.88 0.46 26.31 Costing study
Full blood count, per test 32.28 4.04 0.28 36.59 Costing study
CD4 count, per test 7.38 9.04 1.37 17.79 Costing study
CM-specific treatment
 Trial drug
  Fluconazole per 1200 mg 0.55 0.55 Provider
  Flucytosine per 500 mg 1.53 1.53 Provider
  Amphotericin B per 1 mg 1.18 1.18 Provider
 Antibiotics
  Flucloxacillin per day 0.2 0.2 Pharmacy
  Gentamicin per day 0.26 0.26 Pharmacy
  Ceftriaxone per ampoule 0.52 0.52 Pharmacy
  Amoxicillin/ampicillin per ampoule 0.066 0.066 Pharmacy
  Doxycycline per day 0.038 0.038 Pharmacy
  Erythromycin per day 0.144 0.144 Pharmacy
  Ciprofloxacin per day 0.10 0.10 Pharmacy
Other intervention
 Potassium 0.105 0.105 Pharmacy
 Magnesium 1.45 1.45 Pharmacy
Blood transfusion per unit 35 35 Hospital department
 Potassium 2.90 2.90 Costing study
 Sodium 2.90 2.90 Costing study
Abbreviations: CM, cryptoccocal meningitis; CSF, cerebrospinal fluid. 
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statuses, from the next of kin (the participants were re-con-
sented on recovery).
RESULTS
The ACTA trial analysis comprised 678 eligible participants 
[6]. Only 4 patients were lost to follow-up. The total mortality 
at 10 weeks (Table 3) was 251 (37%) overall, and was lowest 
for 1 week of AmB and 5FC (24%, 95% confidence interval 
[CI] 16–31) [6].
Resource Use, Costs, and Health Outcomes
The unit prices are shown in Table 1. The cost per bed-day was 
$48 in 2015 US$. This excludes CM treatment–specific costs 
and laboratory test costs. Detailed resource use by trial arm is 
presented in Table 2. The differences between the trial arms in 
Table 2. Mean (SD) Resource Use per Patient by Trial Arm, Over 10-Week Trial Period
Service Use Item
Service  
Use Item
2 Weeks of  
Oral FLU and 5FC
1 Week of  
AmB and FLU
 1 Week of  
AmB and 5FC
2 Weeks of  
AmB and FLU
 2 Weeks of  
AmB and 5FC
Hospitalization Days 17.33 (15.29) 17.14 (18.04) 17.99 (15.06) 16.09 (12.27) 19.31 (18.31)
Re-hospitalization Days 2.02 (5.23) 2.14 (6.31) 0.88 (2.72) 1.77 (5.48) 1.38 (4.10)
CM-specific treatment
 Trial drug
  Fluconazole Tablet (200 mg) 187.96 (123.83) 147.18 (130.65) 161.50 (148.25) 170.68 (125.26) 120.37 (159.31)
  Flucytosine Tablet (500 mg) 131 (56) 0.00 (0.00) 74 (23) 0.00 (0.00) 131 (59)
  Amphotericin B Vial (50 mg) 0.00 (0.00) 6.50 (2.60) 7.35 (2.12) 12.71 (5.53) 13.07 (5.94)
 Antibiotics
  Flucloxacillin Times 0.03 (0.17) 0.06 (0.24) 0.05 (0.23) 0.13 (0.34) 0.09 (0.28)
  Gentamicin Times 0.02 (0.13) 0.00 (0.00) 0.01 (0.09) 0.02 (0.13) 0.03 (0.18)
  Ceftriaxone Ampoule 0.62 (0.49) 0.65 (0.48) 0.58 (0.50) 0.60 (0.49) 0.66 (0.48)
  Amoxicillin/ampicillin Ampoule 0.06 (0.24) 0.06 (0.24) 0.11 (0.31) 0.07 (0.26) 0.04 (0.20)
  Doxycycline Times 0.01 (0.09) 0.05 (0.21) 0.00 (0.00) 0.04 (0.18) 0.01 (0.09)
  Erythromycin Times 0.00 (0.00) 0.01 (0.09) 0.01 (0.09) 0.01 (0.09) 0.00 (0.00)
  Ciprofloxacin Times 0.05 (0.22) 0.03 (0.16) 0.04 (0.21) 0.04 (0.21) 0.01 (0.09)
 Other intervention
  Potassium Days 0.00 (0.00) 6.05 (2.20) 6.72 (1.43) 11.71 (4.41) 11.83 (4.62)
  Magnesium Days 0.00 (0.00) 6.05 (2.20) 6.72 (1.43) 11.71 (4.41) 11.83 (4.62)
Blood transfusion Units 0.12 (0.52) 0.23 (0.66) 0.15 (0.57) 0.31 (0.73) 0.37 (0.86)
Lumbar puncture Times 3.13 (1.84) 2.62 (1.07) 3.26 (1.39) 2.93 (1.59) 2.98 (1.44)
Bio-chemistry
 Total Bilirubin Times 1.69 (2.95) 1.57 (2.77) 1.74 (2.99) 1.44 (2.79) 1.63 (2.94)
 CRP Times 0.06 (0.31) 0.09 (0.39) 0.04 (0.21) 0.11 (0.42) 0.10 (0.41)
 ALT Times 3.48 (2.09) 3.04 (1.73) 3.69 (2.00) 3.66 (2.32) 3.40 (1.99)
 Magnesium Times 0.19 (0.73) 0.20 (0.75) 0.20 (0.67) 0.16 (0.66) 0.22 (0.81)
 Potassium Times 7.00 (3.15) 6.23 (3.21) 7.22 (2.35) 7.07 (3.12) 6.83 (3.21)
 Sodium Times 7.02 (3.09) 6.25 (3.21) 7.27 (2.41) 7.12 (3.14) 6.90 (3.23)
 Urea Times 6.99 (3.12) 6.22 (3.14) 7.19 (2.44) 7.04 (3.07) 6.79 (3.12)
 Creatinine Times 7.15 (3.17) 6.32 (3.32) 7.39 (2.45) 7.18 (3.12) 6.98 (3.29)
 Proteinuria Times 7.64 (3.48) 6.82 (3.80) 7.82 (2.71) 7.87 (3.63) 7.47 (3.65)
Full blood count Times 4.62 (2.39) 4.26 (2.62) 4.68 (1.96) 4.69 (2.41) 4.63 (2.60)
CD4 count Times 0.97 (0.37) 1.01 (0.37) 0.93 (0.29) 0.97 (0.45) 0.98 (0.30)
Microbiologya
 Urine culture: negative Times 0.08 (0.34) 0.07 (0.32) 0.04 (0.19) 0.11 (0.36) 0.09 (0.45)
 Urine culture: positive Times 0.05 (0.26) 0.04 (0.23) 0.02 (0.13) 0.04 (0.18) 0.02 (0.13)
 Blood culture: negative Times 0.12 (0.36) 0.08 (0.27) 0.10 (0.33) 0.12 (0.44) 0.10 (0.40)
 Blood culture: positive Times 0.07 (0.27) 0.09 (0.35) 0.04 (0.19) 0.13 (0.45) 0.04 (0.24)
 Sputum culture: negative Times 0.00 (0.00) 0.00 (0.00) 0.01 (0.09) 0.00 (0.00) 0.00 (0.00)
 Sputum culture: positive Times 0.07 (0.27) 0.09 (0.35) 0.07 (0.29) 0.06 (0.28) 0.08 (0.27)
 CSF: negative Times 0.64 (0.88) 0.77 (0.99) 1.27 (1.04) 0.75 (0.84) 1.34 (1.21)
 CSF: positive Times 2.44 (1.88) 1.83 (1.14) 1.95 (1.39) 2.17 (1.63) 1.56 (1.02)
Abbreviations: 5FC, flucytosine; ALT, alanine aminotransferase; AmB, amphotericin B; CM, cryptoccocal meningitis; CRP, C-reactive protein; CSF, cerebrospinal fluid; FLU, fluconazole; SD, 
standard deviation. 
aNegative cultures are less costly than positive cultures.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy971/5377300 by St G
eorge's U
niversity of London user on 15 M
arch 2019
 • CID 2019:XX (XX XXXX) • 5Cost-Effectiveness of Antifungals
resource use were largely driven by the component drugs and 
complication-related resource use. Thus, blood transfusions 
and potassium and magnesium supplementation were highest 
for participants in the 2-week AmB arms and lowest for the 
oral 5FC and FLU combination. The duration of hospitalization 
was largely similar between the trial arms, as this was proto-
col-driven. Participants were asked to remain in the hospital as 
inpatients for at least 14 days for trial safety monitoring.
Mean per patient total costs were lowest for the oral 5FC and 
FLU combination (US $1442) and highest for 2 weeks of AmB 
and 5FC (US $2285; Table  3). The total cost of bed-days per 
patient (both from hospitalization and re-hospitalization) was 
the major cost component, ranging from 36% of the costs for 2 
weeks of AmB and FLU to 56% of the costs for the oral arm. More 
than 75% of the costs were incurred during the first 2 weeks.
Cost-Effectiveness and Uncertainty
We determined that 1 week of AmB and 5FC was less costly and 
more effective than (ie, dominated) 2 weeks of AmB and 5FC 
(Table 3 and Figure 1). While 2 weeks of oral 5FC and FLU was 
also less costly than 2 weeks of AmB and 5FC, the reduction in 
mortality was marginal (Table  3 and Figure  1). Both 2 weeks 
of AmB and FLU and 1 week of AmB and FLU were cost-sav-
ing when compared with 2 weeks of AmB and 5FC, but these 
treatments were associated with increased mortality (Table  3 
and Figure 1).
Therefore, 1 week of AmB and 5FC and 2 weeks of oral 
combination were the 2 most attractive induction treatments. 
Figure 2 shows the uncertainty around the health-service cost 
savings, in relation to the number of lives saved, in scatter plots 
of the cost-effectiveness plane. In comparison to 2 weeks of 
AmB and 5FC, 2 weeks of oral 5FC and FLU is robustly cost 
saving, but the health gain is much less certain. In comparison, 
1 week of AmB and 5FC shows a robust reduction in both cost 
and deaths. Finally, in a head-to-head comparision (Table  3, 
right side) 1 week of AmB and 5FC shows a robust health gain, 
at some additional cost, compared with the oral 5FC and FLU 
regimen (US $208 per life-year gained, 95% CI $91–1210).
Figure 2 shows the probability (y-axis) that 1 week of AmB 
and 5FC is cost-effective when compared with 2 weeks of oral 
5FC and FLU at the complete, full range of willingness-to-pay 
thresholds (x-axis). The probability of a course of treatment 
being cost-effective exceeds 90% at a threshold of US $490 and 
is around 80% at a threshold of US $330 per life-year saved.
Multi-variate Sensitivity Analysis
We varied all the resource parameters (Table 2) and the health 
outcomes (Table  3) in an empirical, multi-variate sensitivity 
analysis (Figure 3). The top 5 drivers of the incremental cost-ef-
fectiveness ratio were mortality rate, life expectancy, number 
of bed-days hospitalized, number of re-hospitalization days, 
and total AmB dosage. The latter and all other parameters did 
not substantially influence the incremental cost-effectiveness 
results. The tornado graph in Figure 3 shows the effect of vary-
ing the value for each important parameter on the incremental 
cost-effectiveness ratio of 1 week of AmB and 5FC, compared 
with the oral regimen, given the uncertainty ranges in the indi-
vidual parameters in probabilistic analyses. If the mortality for 1 
week of AmB and 5FC was varied from 16% to 31% (ie, the lower 
and upper 95% CI of the mortality estimate), then the incremen-
tal cost-effectiveness ratio would vary between $121 and $638, 
assuming other parameters were constant.
DISCUSSION
This study shows that 1 week of AmB and 5FC and oral FLU 
and 5FC were the most cost-effective regimens, and either is 
suitable to replace 2 weeks of AmB and 5FC as the preferred 
regimen in many settings. In comparison with 2 weeks of AmB 
and 5FC, both regimens were less costly and 1 week of AmB and 
5FC led to substantial health gains, while the oral combination 
was at least as effective.
The findings for 1 week of AmB and 5FC were very robust. 
Even when the mortality of 1 week of AmB and 5FC was var-
ied to the upper 95% CI limit of 31%, 1 week of AmB and 5FC 
still dominated 2 weeks of AmB and 5FC. In an arm-to-arm 
comparison, the estimated incremental cost-effectiveness ratio 
Table 3. Probabilistic Cost-effectiveness Analyses, Comparing the Trial Arms in Terms of Mean Total Health Care Costs and Death Rate (%)
Total Cost per Patient and  
Death Rate (%) Per Arm
Incremental Comparison of 1 Week of AmB and 5FC 
 Versus 2 Weeks of FLU and 5FC
ACTA Treatment Arms Mean Total Costs Deaths (%)
Incremental Costs 
per Patient
Incremental  
Death Rate (%)
Incremental Costs Per 
Life-year Saved
2 weeks of oral FLU and 5FC 1442 (1336–1565) 35 (28–41) Reference Reference Reference
1 week of AmB and FLU 1763 (1567–1979) 49 (39–58) ... ... ...
1 week of AmB and 5FC 1861 (1724–2033) 24 (16–31) 419 (236–619) 11 (0.6–21) 208 (91–1210)
2 weeks of AmB and FLU 2125 (1946–2313) 41 (32–49) ... ... ...
2 weeks of AmB and 5FC (Comparator) 2285 (2070–2525) 38 (29–46) ... ... ...
Compared to other treatment combinations, 2 weeks of oral treatment and 1 week of AmB and 5FC showed lower costs and better health outcomes (ie, cost less and averted more deaths). 
In economic terms, these 2 treatments dominate the other options. The incremental cost-effectiveness is shown for these remaining favorable options on the right half of the table. The 
average estimated life expectancy is 18 years, as reported in Rajasingham et al’s study [11]. The numbers in parentheses are estimates of the 95% confidence intervals, as estimated by 
boot-strapping. Abbreviations: 5FC, flucytosine; AmB, amphotericin B; FLU, fluconazole.
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for 1 week of AmB and 5FC versus oral 5FC and FLU was 
$208 per life-year saved. In clinical settings in Africa where 
AmB can be given and monitored, 1 week of AmB and 5FC 
represents a cost-effective option. Importantly, however, oral 
fluconazole and flucytosine provides a cost-effective option for 
more severely resource-limited settings, where AmB therapy is 
Figure 2. Cumulative probability of the incremental cost-effectiveness ratio being 
below different thresholds for the comparison of 1 week of AmB and 5FC versus oral 
FLU and 5FC. Abbreviations: 5FC, flucytosine; AmB, amphotericin B; FLU, fluconazole.
Figure 3. Tornado diagram of ICER for 1 week of AmB and 5FC vs an oral com-
bination for major components. All other resource parameters were not influential. 
The analyses use the 95% of the input distribution for resource use and health 
outcomes parameters to eliminate extreme outliers. The input ranges are based 
on the overall results from bootstrap methods described in the methods section, 
using individual participant data. Life expectancy input data are from a comparable 
cohort [11, 17] Abbreviations: 5FC, flucytosine; AmB, amphotericin B; CI, confidence 
interval; ICER, incremental cost-effectiveness ratio.
Figure 1. Cost-effectiveness planes after bootstrap iterations (1000 selected at random are shown) to present incremental costs and death prevented (%) after the 10-week 
trial period, for (A) oral 5FC and FLU versus 2 weeks of AmB and 5FC, (B) 1 week of AmB and 5FC versus 2 weeks of AmB and 5FC, and (C) 1 week of AmB and 5FC versus oral 
FLU and 5FC. The ellipses show 95% confidence intervals. The red dots indicate the means for both axes. Abbreviations: 5FC, flucytosine; AmB, amphotericin B; FLU, fluconazole.
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not possible; that is, it is as effective as the current international 
standard of care and reduces service costs. The findings re-em-
phasize the absolute necessity of current international efforts to 
secure immediate and wide access to flucytosine.
This is the first large study based on the collection of pro-
tocol-driven, patient-level resource-use data across differ-
ent African countries. These data were supplemented with 
medical and nursing staff time information and an empirical 
costing study in the Zambian public hospital site. Here, as in 
many other sub-Saharan African countries, costs data are not 
included in routine health-service data collection. Therefore, as 
part of ACTA, we undertook substantial efforts to obtain reli-
able, consistent, and accurate data on components of the ser-
vice costs per bed-day, the main driver of total costs per patient. 
The resulting cost per bed-day was relatively high (US $48): it 
reflected the real-life local cost of intensive treatment and local 
procurement, and excluded CM treatment–specific costs and 
specific laboratory-test costs.
In a prior study to compare the cost-effectiveness of alter-
native regimens, Rajasingham et al concluded that 1 week of 
AMB plus fluconazole would likely be much more cost-ef-
fective than 2 weeks of AmB courses [11]. A  limitation 
acknowledged by the authors was that the efficacy compo-
nent was based on the pooled mortality data available at that 
time across small, often non-comparative studies and from 
different settings. Our service costs and resource-use data 
are linked to the largest trial to date. The results confirm the 
economic attractiveness of 1 week of AmB in relation to 2 
weeks of AmB, in terms of cost savings and higher effective-
ness, but only in combination with 5FC as the partner drug. 
They also demonstrate the attractiveness of the combination 
of the 2 oral drugs: fluconazole and 5FC. The 1-week course 
with AmB comes at an additional price compared wth oral 
FLU and 5FC, which may be affordable in many sub-Saha-
ran Africa country settings, and compares well with a range 
of other clinical interventions, including the prevention of 
mother-to-child HIV transmission, multidrug-resistant 
tuberculosis treatment, and intrapartum care [18–20].
The cost-effectiveness advantage of 1 week of AmB and 5FC 
and oral FLU and 5FC, as compared to 2 weeks of AmB regi-
mens, is underestimated in our analysis. We measured actual 
durations of hospitalization of the ACTA trial participants, 
which, for trial safety monitoring reasons, required participants 
to be hospitalized under close observation for the first 2 weeks. 
In real-life implementation, the duration of hospitalization for 
patients on either regimen would, in all likelihood, be lower; 
therefore, the cost of these regimens would decrease in relation 
to 2 weeks of AmB regimens, which require a minimum dura-
tion of hospitalization of 14 days. If we included all societal cost 
consequences, including those at the household level, the total 
societal cost savings of either regimen over 2 weeks of AmB 
regimen would increase further, as travel and loss of household 
productivity in relation to hospitalization would be reduced, as 
well as the out-of pocket patient-related costs born by carers.
In an explorative scenario, we subtracted the cost of the sec-
ond week’s admission from the total for any patient discharged 
on day 14 or earlier who was on oral treatment or on 1 week 
of AmB and 5FC (using the original trial data). This shorter 
hospital-stay scenario results in a total per patient cost of US 
$767 (95% CI 722–841) for the oral arm and US $1161 (95% CI 
1114–1225) for 1 week of AmB. These costs are about half those 
of the per-protocol hospital stays for patients on these arms 
and are substantially lower than the costs of 2 weeks of AmB 
and 5FC ($2285), making both regimins even more attractive. 
Importantly, the incremental cost-effectiveness of 1 week of 
AmB and 5FC versus the oral combination would not be altered 
by this consideration, since all CM patients require some period 
of hospitalization for optimal care, including the measurement 
and management of raised cerebrospinal fluid pressure.
This study provides further strong support for the recent-
ly-updated World Health Organization guidelines for the treat-
ment of HIV-associated CM, which recommend 1 week of AmB 
and 5FC and oral FLU and 5FC as the first and second preferred 
regimens. Flucytosine needs to be made available widely to 
reduce cryptococcal-associated mortality.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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